Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sebastian Frechen

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
Journal of Palliative Medicine|July 6, 2010
Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility projectJan Gaertner, Juergen Wolf, Dennis Scheicht, et al.
The AAPS Journal|August 20, 2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer PatientsAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 17, 2014
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinibAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamHannah Britz, Nina Hanke, Anke-Katrin Volz, et al.
Breast Care (Basel, Switzerland)|July 23, 2011
Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot ProjectJan Gaertner, Rachel Wuerstlein, Ursula Klein, et al.
Pharmacology|April 23, 2016
Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum SamplesAli Sigaroudi, Christoph Stelzer, Tina Braun, et al.
Clinical Pharmacokinetics|May 9, 2013
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazoleSebastian Frechen, Lisa Junge, Teijo I Saari, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill PatientsMax Taubert, Michael Zoller, Barbara Maier, et al.
Journal of Clinical Pharmacology|May 1, 2014
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolamDorota Tomalik-Scharte, Ahmed Abbas Suleiman, Sebastian Frechen, et al.
British Journal of Clinical Pharmacology|September 2, 2018
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humansNiladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Palliative Medicine|July 6, 2010
Implementing WHO recommendations for palliative care into routine lung cancer therapy: a feasibility projectJan Gaertner, Juergen Wolf, Dennis Scheicht, et al.
The AAPS Journal|August 20, 2015
A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer PatientsAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 17, 2014
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinibAhmed Abbas Suleiman, Sebastian Frechen, Matthias Scheffler, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamHannah Britz, Nina Hanke, Anke-Katrin Volz, et al.
Breast Care (Basel, Switzerland)|July 23, 2011
Integrating Palliative Medicine into Comprehensive Breast Cancer Therapy - a Pilot ProjectJan Gaertner, Rachel Wuerstlein, Ursula Klein, et al.
Pharmacology|April 23, 2016
Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum SamplesAli Sigaroudi, Christoph Stelzer, Tina Braun, et al.
Clinical Pharmacokinetics|May 9, 2013
A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazoleSebastian Frechen, Lisa Junge, Teijo I Saari, et al.
Antimicrobial Agents and Chemotherapy|June 22, 2016
Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill PatientsMax Taubert, Michael Zoller, Barbara Maier, et al.
Journal of Clinical Pharmacology|May 1, 2014
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolamDorota Tomalik-Scharte, Ahmed Abbas Suleiman, Sebastian Frechen, et al.
British Journal of Clinical Pharmacology|September 2, 2018
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humansNiladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, et al.
Pageof 5